NASDAQ:CERO CERo Therapeutics (CERO) Stock Price, News & Analysis → The best inflation-proof investment (From DTI) (Ad) Free CERO Stock Alerts $1.35 -0.03 (-2.17%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$1.30▼$1.4250-Day Range$1.35▼$3.9552-Week Range$1.30▼$12.80Volume50,227 shsAverage Volume179,761 shsMarket Capitalization$19.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get CERo Therapeutics alerts: Email Address Ad Stansberry ResearchDo NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.Everything you need to know is posted on our website here. About CERo Therapeutics Stock (NASDAQ:CERO)CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Read More CERO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERO Stock News HeadlinesApril 30, 2024 | finance.yahoo.comCERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing AttributesMarch 30, 2024 | msn.comCompare with Bloomberg Emerging Markets Large & Mid Cap Total Return Index NOK (EMTK)May 7, 2024 | Stansberry Research (Ad)Do NOT read if you believe in “woke” politicsI have to warn you, however: This CEO of a publicly traded company is not afraid to mince words. Many on Wall Street have refused to work with him.March 21, 2024 | wsj.comCERo Therapeutics Holdings Inc.March 17, 2024 | morningstar.comCERo Therapeutics Holdings Inc CEROMarch 11, 2024 | finance.yahoo.comCERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML PatientsSee More Headlines Receive CERO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:CERO Previous SymbolNASDAQ:CERO CUSIPN/A CIK1870404 Webwww.cero.bio Phone215-731-9450FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,720,000Free Float12,398,000Market Cap$19.87 million OptionableN/A Beta-0.08 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Daniel Mark Corey M.D. (Age 45)Founder, CTO & Director Comp: $372.69kMr. Brian G. Atwood (Age 71)President, CEO & Chairman Mr. Charles Ross Carter (Age 56)CFO, Treasurer & Corporate Secretary Dr. Robert Sikorski M.D. (Age 61)Ph.D., Consultant Key CompetitorsPsyence BiomedicalNASDAQ:PBMPrenetics GlobalNASDAQ:PREFuture Health ESGNASDAQ:FHLTMEI PharmaNASDAQ:MEIPT2 BiosystemsNASDAQ:TTOOView All Competitors CERO Stock Analysis - Frequently Asked Questions How have CERO shares performed in 2024? CERo Therapeutics' stock was trading at $4.78 at the beginning of the year. Since then, CERO stock has decreased by 71.8% and is now trading at $1.35. View the best growth stocks for 2024 here. How do I buy shares of CERo Therapeutics? Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERO) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
